GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (NAS:BLFS) » Definitions » Beneish M-Score

BioLife Solutions (BioLife Solutions) Beneish M-Score : -3.47 (As of Apr. 26, 2024)


View and export this data going back to 1992. Start your Free Trial

What is BioLife Solutions Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.47 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for BioLife Solutions's Beneish M-Score or its related term are showing as below:

BLFS' s Beneish M-Score Range Over the Past 10 Years
Min: -3.47   Med: -2.14   Max: -0.4
Current: -3.47

During the past 13 years, the highest Beneish M-Score of BioLife Solutions was -0.40. The lowest was -3.47. And the median was -2.14.


BioLife Solutions Beneish M-Score Historical Data

The historical data trend for BioLife Solutions's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLife Solutions Beneish M-Score Chart

BioLife Solutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.73 -2.18 -0.40 -2.67 -3.47

BioLife Solutions Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.67 -3.05 -3.40 -3.42 -3.47

Competitive Comparison of BioLife Solutions's Beneish M-Score

For the Medical Instruments & Supplies subindustry, BioLife Solutions's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLife Solutions's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where BioLife Solutions's Beneish M-Score falls into.



BioLife Solutions Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of BioLife Solutions for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.6207+0.528 * 1.0197+0.404 * 1.0385+0.892 * 0.8857+0.115 * 1.0808
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.3098+4.679 * -0.113917-0.327 * 0.9785
=-3.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $18.7 Mil.
Revenue was 32.733 + 33.328 + 39.508 + 37.703 = $143.3 Mil.
Gross Profit was 9.25 + 11.649 + 11.812 + 14.039 = $46.8 Mil.
Total Current Assets was $120.6 Mil.
Total Assets was $412.7 Mil.
Property, Plant and Equipment(Net PPE) was $32.6 Mil.
Depreciation, Depletion and Amortization(DDA) was $12.3 Mil.
Selling, General, & Admin. Expense(SGA) was $80.3 Mil.
Total Current Liabilities was $42.2 Mil.
Long-Term Debt & Capital Lease Obligation was $32.7 Mil.
Net Income was -13.382 + -29.132 + -10.199 + -13.714 = $-66.4 Mil.
Non Operating Income was 0.652 + -13.663 + 6.423 + -0.326 = $-6.9 Mil.
Cash Flow from Operations was 2.311 + -4.379 + -7.718 + -2.712 = $-12.5 Mil.
Total Receivables was $33.9 Mil.
Revenue was 44.259 + 40.747 + 40.533 + 36.22 = $161.8 Mil.
Gross Profit was 13.971 + 13.738 + 14.339 + 11.774 = $53.8 Mil.
Total Current Assets was $138.5 Mil.
Total Assets was $450.2 Mil.
Property, Plant and Equipment(Net PPE) was $39.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $16.5 Mil.
Selling, General, & Admin. Expense(SGA) was $69.2 Mil.
Total Current Liabilities was $44.6 Mil.
Long-Term Debt & Capital Lease Obligation was $38.9 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(18.657 / 143.272) / (33.936 / 161.759)
=0.130221 / 0.209794
=0.6207

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(53.822 / 161.759) / (46.75 / 143.272)
=0.33273 / 0.326302
=1.0197

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (120.604 + 32.617) / 412.714) / (1 - (138.452 + 39.202) / 450.229)
=0.628748 / 0.605414
=1.0385

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=143.272 / 161.759
=0.8857

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(16.472 / (16.472 + 39.202)) / (12.295 / (12.295 + 32.617))
=0.295865 / 0.273758
=1.0808

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(80.308 / 143.272) / (69.223 / 161.759)
=0.560528 / 0.427939
=1.3098

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((32.685 + 42.178) / 412.714) / ((38.881 + 44.582) / 450.229)
=0.181392 / 0.185379
=0.9785

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-66.427 - -6.914 - -12.498) / 412.714
=-0.113917

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

BioLife Solutions has a M-score of -3.47 suggests that the company is unlikely to be a manipulator.


BioLife Solutions Beneish M-Score Related Terms

Thank you for viewing the detailed overview of BioLife Solutions's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLife Solutions (BioLife Solutions) Business Description

Traded in Other Exchanges
Address
3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.
Executives
Geraint Phillips officer: SVP, Global Operations 3303 MONTE VILLA, #310, BOTHELL WA 98021
Sarah Aebersold officer: VP, Global Human Resources BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Troy Wichterman officer: Chief Financial Officer 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Greef Roderick De director
Aby J. Mathew officer: Chief Tech. Officer & Sr. VP 3303 MONTE VILLA PARKWAY, #310, BOTHELL WA 98021
Todd Berard officer: Vice President, Marketing 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Karen A. Foster officer: Vice President of Operations C/O BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Michael Rice director, officer: President & CEO C/O BIOLIFE SOLUTIONS, INC., 171 FRONT STREET, OWEGO NY 13827
Casdin Partners Master Fund, L.p. 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Garrie Richardson officer: Chief Revenue Officer 3303 MONTE VILA PARKWAY, BOTHELL WA 98021
Marcus Schulz officer: Vice President, Global Sales 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Joseph C Schick director 16719 NE 139TH PLACE, WOODINVILLE WA 98072
Amy Duross director 8410 GOLDEN BEAR PLACE, WHISTLER A1 V8E 1J7
Timothy L. Moore director C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Joydeep Goswami director SUMITOMO FUDOSAN MITA TWIN BLDG, EAST WING 4-2-8 SHIBAURA MINATO-KU, TOKYO M0 1080023